Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population

David T Gamble, Allan B. Clark, Robert N. Luben, Nicholas J. Wareham, Kay-Tee Khaw, Phyo K. Myint

Research output: Contribution to journalArticle

1 Citation (Scopus)
4 Downloads (Pure)

Abstract

Background: Stroke is primarily a disease of older age with a substantial impact on global mortality and morbidity. Whilst medications with anticholinergic effects are widely used, no studies have been conducted to examine the relationship between anticholinergic burden (ACB) and stroke in a general population. Method: The sample was drawn from the EPIC-Norfolk cohort. Baseline assessments were carried out during 1993-1997 and participants were followed up until March 2016. Participants were divided into 4 groups according to their total ACB score at baseline, these groups were those with a total ACB score of 0, 1, 2-3 and >3. After exclusion, Cox-proportional hazards models were constructed to determine the associations between the ACB score groups and the risk of incident stroke and stroke mortality. Sensitivity analysis and propensity score matched analyses were performed. Results: In total 25,639 participants attended the first health check, 3,917 participants were excluded, leaving 21,722 participants to be included. Participants had a mean age (SD) of 58.9 (9.2) years (54.4% women). Of these, 2,131 suffered incident stroke and 562 died from stroke. Mean follow up was approximately 18 years for both outcomes. In the fully adjusted model, those with an ACB of >3 had 59% relative risk of incident stroke (HR (95% CI) 1.59 (1.34 - 1.89)) and 86% relative risk of stroke mortality (1.86 (1.37 - 2.53)) compared to those in ACB 0 category. Sensitivity analyses and propensity score matched analyses showed similar results. Conclusions: Our results provide an incentive for the cautious use of medications with anticholinergic properties to help reduce the global burden of stroke.
Original languageEnglish
Pages (from-to)625-633
Number of pages9
JournalInternational Journal of Epidemiology
Volume47
Issue number2
Early online date14 Feb 2018
DOIs
Publication statusPublished - 1 Apr 2018

Fingerprint

Cholinergic Antagonists
Stroke
Population
Propensity Score
Mortality
Proportional Hazards Models
Motivation
Morbidity
Health

Keywords

  • anticholinergic burden
  • stroke
  • mortality
  • incidence
  • epidemiology

Cite this

Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population. / Gamble, David T; Clark, Allan B.; Luben, Robert N.; Wareham, Nicholas J.; Khaw, Kay-Tee; Myint, Phyo K.

In: International Journal of Epidemiology, Vol. 47, No. 2, 01.04.2018, p. 625-633.

Research output: Contribution to journalArticle

Gamble, David T ; Clark, Allan B. ; Luben, Robert N. ; Wareham, Nicholas J. ; Khaw, Kay-Tee ; Myint, Phyo K. / Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population. In: International Journal of Epidemiology. 2018 ; Vol. 47, No. 2. pp. 625-633.
@article{3418a81dc875492c98f375235c6a25e0,
title = "Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population",
abstract = "Background: Stroke is primarily a disease of older age with a substantial impact on global mortality and morbidity. Whilst medications with anticholinergic effects are widely used, no studies have been conducted to examine the relationship between anticholinergic burden (ACB) and stroke in a general population. Method: The sample was drawn from the EPIC-Norfolk cohort. Baseline assessments were carried out during 1993-1997 and participants were followed up until March 2016. Participants were divided into 4 groups according to their total ACB score at baseline, these groups were those with a total ACB score of 0, 1, 2-3 and >3. After exclusion, Cox-proportional hazards models were constructed to determine the associations between the ACB score groups and the risk of incident stroke and stroke mortality. Sensitivity analysis and propensity score matched analyses were performed. Results: In total 25,639 participants attended the first health check, 3,917 participants were excluded, leaving 21,722 participants to be included. Participants had a mean age (SD) of 58.9 (9.2) years (54.4{\%} women). Of these, 2,131 suffered incident stroke and 562 died from stroke. Mean follow up was approximately 18 years for both outcomes. In the fully adjusted model, those with an ACB of >3 had 59{\%} relative risk of incident stroke (HR (95{\%} CI) 1.59 (1.34 - 1.89)) and 86{\%} relative risk of stroke mortality (1.86 (1.37 - 2.53)) compared to those in ACB 0 category. Sensitivity analyses and propensity score matched analyses showed similar results. Conclusions: Our results provide an incentive for the cautious use of medications with anticholinergic properties to help reduce the global burden of stroke.",
keywords = "anticholinergic burden, stroke, mortality, incidence, epidemiology",
author = "Gamble, {David T} and Clark, {Allan B.} and Luben, {Robert N.} and Wareham, {Nicholas J.} and Kay-Tee Khaw and Myint, {Phyo K.}",
note = "The EPIC-Norfolk study was supported by grants from the Medical Research Council (G1000143) and Cancer Research UK (14136). Funders and sponsors had no role in design, interpretation or writing of the article.",
year = "2018",
month = "4",
day = "1",
doi = "10.1093/ije/dyx265",
language = "English",
volume = "47",
pages = "625--633",
journal = "International Journal of Epidemiology",
issn = "0300-5771",
publisher = "OXFORD UNIV PRESS",
number = "2",

}

TY - JOUR

T1 - Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population

AU - Gamble, David T

AU - Clark, Allan B.

AU - Luben, Robert N.

AU - Wareham, Nicholas J.

AU - Khaw, Kay-Tee

AU - Myint, Phyo K.

N1 - The EPIC-Norfolk study was supported by grants from the Medical Research Council (G1000143) and Cancer Research UK (14136). Funders and sponsors had no role in design, interpretation or writing of the article.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Stroke is primarily a disease of older age with a substantial impact on global mortality and morbidity. Whilst medications with anticholinergic effects are widely used, no studies have been conducted to examine the relationship between anticholinergic burden (ACB) and stroke in a general population. Method: The sample was drawn from the EPIC-Norfolk cohort. Baseline assessments were carried out during 1993-1997 and participants were followed up until March 2016. Participants were divided into 4 groups according to their total ACB score at baseline, these groups were those with a total ACB score of 0, 1, 2-3 and >3. After exclusion, Cox-proportional hazards models were constructed to determine the associations between the ACB score groups and the risk of incident stroke and stroke mortality. Sensitivity analysis and propensity score matched analyses were performed. Results: In total 25,639 participants attended the first health check, 3,917 participants were excluded, leaving 21,722 participants to be included. Participants had a mean age (SD) of 58.9 (9.2) years (54.4% women). Of these, 2,131 suffered incident stroke and 562 died from stroke. Mean follow up was approximately 18 years for both outcomes. In the fully adjusted model, those with an ACB of >3 had 59% relative risk of incident stroke (HR (95% CI) 1.59 (1.34 - 1.89)) and 86% relative risk of stroke mortality (1.86 (1.37 - 2.53)) compared to those in ACB 0 category. Sensitivity analyses and propensity score matched analyses showed similar results. Conclusions: Our results provide an incentive for the cautious use of medications with anticholinergic properties to help reduce the global burden of stroke.

AB - Background: Stroke is primarily a disease of older age with a substantial impact on global mortality and morbidity. Whilst medications with anticholinergic effects are widely used, no studies have been conducted to examine the relationship between anticholinergic burden (ACB) and stroke in a general population. Method: The sample was drawn from the EPIC-Norfolk cohort. Baseline assessments were carried out during 1993-1997 and participants were followed up until March 2016. Participants were divided into 4 groups according to their total ACB score at baseline, these groups were those with a total ACB score of 0, 1, 2-3 and >3. After exclusion, Cox-proportional hazards models were constructed to determine the associations between the ACB score groups and the risk of incident stroke and stroke mortality. Sensitivity analysis and propensity score matched analyses were performed. Results: In total 25,639 participants attended the first health check, 3,917 participants were excluded, leaving 21,722 participants to be included. Participants had a mean age (SD) of 58.9 (9.2) years (54.4% women). Of these, 2,131 suffered incident stroke and 562 died from stroke. Mean follow up was approximately 18 years for both outcomes. In the fully adjusted model, those with an ACB of >3 had 59% relative risk of incident stroke (HR (95% CI) 1.59 (1.34 - 1.89)) and 86% relative risk of stroke mortality (1.86 (1.37 - 2.53)) compared to those in ACB 0 category. Sensitivity analyses and propensity score matched analyses showed similar results. Conclusions: Our results provide an incentive for the cautious use of medications with anticholinergic properties to help reduce the global burden of stroke.

KW - anticholinergic burden

KW - stroke

KW - mortality

KW - incidence

KW - epidemiology

U2 - 10.1093/ije/dyx265

DO - 10.1093/ije/dyx265

M3 - Article

VL - 47

SP - 625

EP - 633

JO - International Journal of Epidemiology

JF - International Journal of Epidemiology

SN - 0300-5771

IS - 2

ER -